Cytosorbents (CTSO) Stock Forecast: StockMap's 2-Week Call

CTSO stock forecast: StockMap's model leans Underperform on Cytosorbents for the two weeks after the Nov 19 close, toward CTSO trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 4 of 6 two-week windows on CTSO since Aug 21; by chance, a call on the same dates was right 59% of the time.

Cytosorbents last closed at $5.13, -7.90% on the session.

Against the IVW growth benchmark the position is -5.57% over the forecast window.

Cytosorbents' market cap is $16.15M as of November 19, 2026.

Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -48 (too close to call).

Where CTSO sits: sized by market cap, coloured by the day's move.

The read is built from 15 underlying insights — 1 bullish and 14 bearish.

Agreement across those insights is 93%.

49 daily calls for CTSO so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

Cytosorbents is classified under Health Care / Health Care Equipment & Supplies.

StockMap tracks Cytosorbents as the 122nd largest of the 141 companies it covers in the Health Care Equipment & Supplies industry, part of the Health Care sector.

Across that group the current two-week reads are 69 Neutral, 55 Moderate Underperform, 14 Strong Underperform and 3 Moderate Outperform.

On that composite Cytosorbents ranks 124th of 141 in the group, against a group median of -0.18.

Other Health Care stocks

Research and education, not investment advice. The calls on this page come from StockMap's automated model, run on the close of November 19, 2026, and are the same for every reader. Calls are graded in public, misses included: how calls are graded, and the record. Who makes the calls and who pays for the site: Disclosures.

Cytosorbents (CTSO) — StockMap 2-week forecast & tracked accuracy